Scientists are moving closer to developing a blood test that could help identify individuals at higher risk of developing lung cancer, a disease that remains one of the deadliest cancers worldwide. Unlike prostate, colon, and breast cancers, screening for lung cancer has been less successful, largely because current screening guidelines focus primarily on smoking history. However, many people who develop lung cancer have never smoked, leaving a significant portion of the population without effective early detection options.
The new blood test aims to flag biomarkers associated with lung cancer risk, potentially enabling earlier diagnosis when the disease is more treatable. This could complement existing screening methods like low-dose CT scans, which are recommended only for high-risk groups such as long-term smokers. The development comes as researchers continue to explore new treatment modalities, including therapies being developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) and others.
Early detection is critical for lung cancer because survival rates improve dramatically when the disease is caught at an early stage. Currently, most lung cancers are diagnosed at advanced stages, when treatment options are limited and prognosis is poor. A simple blood test could revolutionize screening by making it more accessible and inclusive, potentially saving thousands of lives each year.
The research represents a significant step forward in the fight against lung cancer, which remains the leading cause of cancer death globally. According to the American Cancer Society, lung cancer accounts for about 25% of all cancer deaths, more than colon, breast, and prostate cancers combined. The lack of effective screening for never-smokers has been a major gap in public health efforts.
The blood test is still in development, but the progress reported offers hope for a future where lung cancer can be detected earlier in a broader population. As screening improves, new treatments and therapeutic approaches, such as those under development by Calidi Biotherapeutics and other innovators, could further enhance outcomes for patients.
This advancement underscores the importance of continued investment in cancer research and the potential of liquid biopsies to transform oncology. While challenges remain, the path toward a reliable lung cancer blood test appears increasingly promising.
